People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Orna Therapeutics Holdings, LLC | — | Biotechnology | Series D+ | $120.6M | $2.5B | 2022 |
Morana M. Jovan-Embiricos at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Morana M. Jovan-Embiricos on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John M. McCabe | 1 | 2 |
| Brian M. Goodman | 1 | 1 |
| Sakae M. Asanuma | 1 | 1 |
| Daniel M. Anderson | 1 | 1 |
| Robert M. Marby | 1 | 1 |
| William M. Shen | 1 | 1 |
| Nishla M. Keiser | 1 | 1 |
| Thomas M. Ebeling | 1 | 1 |
| Francesco M. Marincola | 1 | 1 |
| Ansbert M. Gadicke | 1 | 1 |
| Thomas M. Barnes | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.